ERT, a global data and technology company that minimises uncertainty and risk in clinical trials, has acquired Biomedical Systems, a well-recognised provider of reliable imaging, as well as cardiac safety and respiratory data collection solutions.
Financial terms of the transaction were not disclosed.
Coupled with its recent addition of imaging technology invented by the Cleveland Clinic, the acquisition of Biomedical Systems enables ERT to further expand its ability to reduce customer risk and uncertainty when imaging, cardiac safety and respiratory data collection are required.
In particular, the acquisition positions ERT to better meet the significant demand for imaging in clinical trials, which is being driven from regulators’ increasing requests that imaging data be included in submissions.
“This acquisition complements our current capabilities and enables us to quickly scale and fully support our customers’ needs for consistent, accurate and verifiable imaging data without adding administrative burden to investigative sites,” said James Corrigan, President and CEO of ERT.
“We are delighted to welcome Biomedical Systems to the ERT team, and look forward to a seamless transition and continuing to deliver market-leading offerings that solve our clients’ most complex challenges.”
“By merging ERT’s high tech imaging capabilities and Biomedical Systems’ expertise from supporting more than 500 imaging trials, the combined organisation delivers the optimal solution to overcome complex challenges in clinical research,” said Tim Barrett, CEO of Biomedical Systems.
“We’re excited to apply our combined 70 years of experience to further help clinical trial sponsors and CROs accelerate clinical development and bring new medicines to market more efficiently.”
